Tüdőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• EGFR 301
• PD-L1 162
• PD-1 156
• KRAS 97
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• VEGF 23
• mTOR 0
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• TROP2 14
• CTNNB1 0
• RAS 15
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

86+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, Egyesült Államok· until 2031. szept.

• NIH NIEHS · F31

  PhosFate: Investigating Chemical Hazards, Community Exposures, and Health Risks from Phosphate Fertilizer Manufacturing

  University of South Florida· Tampa, Egyesült Államok· 41 102 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, Egyesült Államok· 77 580 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NCI · R01

  Role of Allostatic Load in Immunotherapy Outcomes

  Ut Southwestern Medical Center· Dallas, Egyesült Államok· 389 844 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 401 115 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spanyolország· EU contribution 262 393 EUR· until 2030. febr.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Svájc· EU contribution 1 874 590 EUR· until 2032. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 216 240 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 426 534 EUR· until 2030. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 1451 running projects, newest first. Listed amounts together: 841,1 M USD + 224,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  PF-07284892 in Participants With Advanced Solid Tumors

  NCT04800822· Pfizer· Frissítve: 2026. jún. 4.

  “The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· National Cancer Institute (NCI)· Frissítve: 2026. ápr. 23.

  “Inadequate accrual rate”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

  NCT06522360· M.D. Anderson Cancer Center· Frissítve: 2025. ápr. 24.

  “0 participants enrolled”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

  NCT03164694· Sun Yat-sen University· Frissítve: 2024. dec. 10.

  “No patients enrolled.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

  NCT05948462· SCRI Development Innovations, LLC· Frissítve: 2023. dec. 13.

  “Study withdrawn by pharmaceutical funding partner”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· TRIANA Biomedicines, Inc.· Forrás

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· AstraZeneca· Forrás

• A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

  NCT03456076· Hoffmann-La Roche· Forrás

• A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

  NCT03194893· Hoffmann-La Roche· Forrás

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· AstraZeneca· Forrás

• Lorlatinib Continuation Study

  NCT05144997· Pfizer· Forrás

• AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

  NCT07617337· Chugai Pharmaceutical· Forrás

• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

  NCT02584933· Novartis Pharmaceuticals· Forrás

• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Hoffmann-La Roche· Forrás

• Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

  NCT06074588· Merck Sharp & Dohme LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 618
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors.

  Oncologist, 2026. okt.

• One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients.

  Anal Methods, 2026. okt.

• Dynamic Predictions in Non-Small Cell Lung Cancer Using Joint Modeling of Longitudinal and Time-To-Event Outcomes Data.

  Cancer Med, 2026. okt.

• Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2-Negative Breast Cancer: A Real-World Study.

  Cancer Med, 2026. okt.

• Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer.

  Clin Cancer Res, 2026. szept.

• Liquid Biopsies for Cancer: A Translational Science Review.

  JAMA, 2026. szept.

• Cell-Free DNA Release Kinetics and Fragmentation Reflect Treatment Response and Resistance In Vitro.

  Cells, 2026. aug.

• Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.

  Virchows Arch, 2026. aug.

• Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non-Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study.

  JMIR Res Protoc, 2026. aug.

• Diagnostic Performance of a Multiplex Circulating Tumor DNA Assay for Lung Cancer Detection.

  J Mol Diagn, 2026. aug.

  Morten Borg

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.